Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's data;
June 1, 2026 10:39 AM EDT
News Briefing
Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
Ahead of ASCO, all eyes on pancreatic cancer
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
Radiopharmaceutical shows promise in post-Pluvicto setting
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
Allogene CEO to step down; Agios drug fails key test
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
A turning point for pancreatic cancer patients
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Cartesian’s $150M financing; Editas Medicine’s money moves
ICON audit found revenue was overstated in 2023 and 2024; Psilera and Secretome Therapeutics raise funds.
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
